Moreover, we identified two novel deletions linked to resistance, involving 16p13.3, CREBBP tumor suppressor genes, and 10p15.3, both involved in the dysregulation of critical specific pathways, such as E2F, MYC targets and G2M checkpoint pathway that have reported to be enriched in MM that fails daratumumab-based regimens [13, 33]. The gene discussed is MYC; the disease is Miyoshi myopathy.